shutterstock_1873015870_alpha_tauri_3d_graphics
Alpha Tauri 3D Graphics / Shutterstock.com
23 August 2022FeaturesBiotechnologyIne Vanderleyden

Microbial consortia and IP in Europe

Our body hosts trillions of microorganisms that live symbiotically on and within the human body. This ‘microbiome’ is essential to our health and microbial imbalance or dysbiosis increases the susceptibility to many diseases, including inflammatory bowel disease (IBD), liver disease, atherosclerosis, and other severe pathologies. Given its central role in health and disease, the microbiome has become a prominent therapeutic target.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
8 April 2026   The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
Biotechnology
7 April 2026   On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.
Biotechnology
27 March 2026   The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.